CA3237750A1 - Microbial compositions for the treatment of skin diseases - Google Patents
Microbial compositions for the treatment of skin diseases Download PDFInfo
- Publication number
- CA3237750A1 CA3237750A1 CA3237750A CA3237750A CA3237750A1 CA 3237750 A1 CA3237750 A1 CA 3237750A1 CA 3237750 A CA3237750 A CA 3237750A CA 3237750 A CA3237750 A CA 3237750A CA 3237750 A1 CA3237750 A1 CA 3237750A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- strain
- seq
- sequence
- bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163278134P | 2021-11-11 | 2021-11-11 | |
| US63/278,134 | 2021-11-11 | ||
| PCT/US2022/079637 WO2023086883A1 (en) | 2021-11-11 | 2022-11-10 | Microbial compositions for the treatment of skin diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3237750A1 true CA3237750A1 (en) | 2023-05-19 |
Family
ID=86336611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3237750A Pending CA3237750A1 (en) | 2021-11-11 | 2022-11-10 | Microbial compositions for the treatment of skin diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US12115197B2 (https=) |
| EP (1) | EP4429683A1 (https=) |
| JP (1) | JP2024544960A (https=) |
| KR (1) | KR20240117164A (https=) |
| CN (1) | CN118541163A (https=) |
| AU (1) | AU2022388745A1 (https=) |
| CA (1) | CA3237750A1 (https=) |
| WO (1) | WO2023086883A1 (https=) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2660645C (en) | 2006-08-11 | 2016-04-05 | Novozymes Biologicals, Inc. | Bacillus cultures for use in washing, cleaning, stain removal, or degrading waste materials |
| KR100878799B1 (ko) * | 2007-03-13 | 2009-01-14 | 한국생명공학연구원 | 항생제 내성 병원성 미생물 또는 장내 유해 미생물의생장을 억제하는 바실러스 아밀로리퀴페시언스 k317 |
| JP2016509003A (ja) * | 2013-02-04 | 2016-03-24 | セレス セラピューティクス インコーポレイテッド | 組成物および方法 |
| US20160073642A1 (en) | 2013-05-03 | 2016-03-17 | Universidad Eafit | Production process for biomass and fengycin metabolites of bacillus species and compositions thereof for biological pest control |
| US20180289751A1 (en) * | 2015-05-05 | 2018-10-11 | The Regents Of The University Of California | Antimicrobial therapy |
| WO2018049182A2 (en) | 2016-09-08 | 2018-03-15 | Locus Solutions, Llc | Distributed systems for the efficient production and use of microbe-based compositions |
| KR20190140063A (ko) | 2017-05-07 | 2019-12-18 | 로커스 아이피 컴퍼니 엘엘씨 | 피부 건강을 위한 화장품 조성물 및 이를 사용하는 방법 |
| EP3784807B1 (en) | 2018-04-23 | 2025-06-04 | Evonik Operations GmbH | Synbiotic compositions |
| US20220096574A1 (en) | 2019-01-29 | 2022-03-31 | Holobiome, Inc. | Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis |
| JP7689077B2 (ja) | 2019-02-11 | 2025-06-05 | エボニック オペレーションズ ゲーエムベーハー | バシラエン産生細菌またはその調製物を含有する組成物 |
| MX2021012558A (es) * | 2019-04-17 | 2022-01-04 | Andes Ag Inc | Metodos innovadores para el tratamiento de las semillas y componentes para mejorar los atributos y el rendimiento de la planta. |
| BR112021023020A2 (pt) | 2019-05-20 | 2022-01-04 | Evonik Operations Gmbh | Uso de ésteres de poliglicerol como carreador para ingredientes microbiológicos ativos |
| MX2021015725A (es) | 2019-06-19 | 2022-04-01 | Basf Corp | Formulaciones agroquimicas acuosas que comprenden esporas de bacterias. |
| GB201911925D0 (en) | 2019-08-20 | 2019-10-02 | Sporegen Ltd | Formulations for prevention or reduction of c. difficile infections |
| CA3187427A1 (en) | 2020-06-17 | 2021-12-23 | Bioconsortia, Inc. | Agriculturally beneficial microbes, microbial compositions, and consortia |
| EP4223301A1 (en) | 2020-09-07 | 2023-08-09 | Il Dong Pharmaceutical Co., Ltd. | Composition for preventing or treating periodontal diseases, comprising bacillus velezensis strain, culture medium thereof, or culture supernatant thereof as active ingredient |
| JP2023543355A (ja) | 2020-09-25 | 2023-10-13 | バイオームエディット・エルエルシー | プロバイオティックバチルス属組成物及び使用方法 |
| WO2022119895A1 (en) | 2020-12-01 | 2022-06-09 | Dupont Us Holding, Llc | Methods and compositions for microbial treatment of skin disorders |
| IL305939A (en) | 2021-03-14 | 2023-11-01 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Bacillus antibacterial agents |
| WO2022226376A2 (en) | 2021-04-22 | 2022-10-27 | Indigo Ag, Inc. | Endophyte compositions and methods for improved plant health |
| WO2023091342A1 (en) | 2021-11-16 | 2023-05-25 | Phibro Animal Health Corporation | Preservation system for stabilizing spore-forming microbials |
-
2022
- 2022-11-10 KR KR1020247018262A patent/KR20240117164A/ko active Pending
- 2022-11-10 EP EP22893839.5A patent/EP4429683A1/en active Pending
- 2022-11-10 AU AU2022388745A patent/AU2022388745A1/en active Pending
- 2022-11-10 WO PCT/US2022/079637 patent/WO2023086883A1/en not_active Ceased
- 2022-11-10 JP JP2024527754A patent/JP2024544960A/ja active Pending
- 2022-11-10 CN CN202280088350.0A patent/CN118541163A/zh active Pending
- 2022-11-10 CA CA3237750A patent/CA3237750A1/en active Pending
-
2024
- 2024-02-28 US US18/589,539 patent/US12115197B2/en active Active
- 2024-09-05 US US18/825,396 patent/US12329787B2/en active Active
-
2025
- 2025-05-12 US US19/205,443 patent/US20250268955A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12329787B2 (en) | 2025-06-17 |
| WO2023086883A1 (en) | 2023-05-19 |
| US20240424033A1 (en) | 2024-12-26 |
| AU2022388745A1 (en) | 2024-05-30 |
| JP2024544960A (ja) | 2024-12-05 |
| US12115197B2 (en) | 2024-10-15 |
| US20250268955A1 (en) | 2025-08-28 |
| US20240189369A1 (en) | 2024-06-13 |
| KR20240117164A (ko) | 2024-07-31 |
| EP4429683A1 (en) | 2024-09-18 |
| CN118541163A (zh) | 2024-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7720639B2 (ja) | 皮膚の酵素活性を制御する分子的細菌療法 | |
| US11590092B2 (en) | Skin probiotic | |
| Erchiga et al. | Malassezia globosa as the causative agent of pityriasis versicolor | |
| Crespo Erchiga et al. | Malassezia globosa as the causative agent of pityriasis versicolor | |
| JP2012070745A (ja) | 病原微生物から皮膚を保護するための方法および手段 | |
| WO2008018143A1 (en) | Moisturizing agent | |
| US20250222045A1 (en) | Bifidobacterium longum subsp. infantis, microbial agent and use thereof | |
| KR20210102871A (ko) | 여드름 치료를 위한 프로프리오니박테리움 아크네스에 대한 세균 요법 | |
| Sav et al. | The frequency, antifungal susceptibility and enzymatic profiles of Candida species in cases of onychomycosis infection | |
| Shah et al. | Role of polyamine transport in Streptococcus pneumoniae response to physiological stress and murine septicemia | |
| US12329787B2 (en) | Microbial compositions for the treatment of skin diseases | |
| JP2012500257A (ja) | エンテロコッカス・フェカリスsl−5由来バクテリオシンの新規な用途 | |
| Sentamilselvi et al. | Trichomycoses | |
| Kush et al. | Evaluation of antimicrobial action of Carie Care™ and Papacarie Duo™ on Aggregatibacter actinomycetemcomitans a major periodontal pathogen using polymerase chain reaction | |
| AL-Hasseny et al. | Molecular Detection of nan, tly and dsA gene of Propionibacterium acnes Isolated from acne vulgaris in Babylon Province | |
| KR102544440B1 (ko) | 피부 상재균으로부터 유래된 엔테로박터 에어로게네스 j2k-739 균주 및 피부 상재균 유래 엔테로박터속을 자극원으로 처리하는 신규한 항주름평가 방법 | |
| EP4527399A1 (en) | Composition for treating ringworm | |
| Kim et al. | Distinct Cutibacterium acnes subspecies defendens strains classified by multi-omics dissection alleviate inflammatory skin lesions of a rosacea-like mouse model | |
| KR102668566B1 (ko) | 수분 친화적 피부 마이크로바이옴에 대한 선택적 조절효능을 가진 락토바실러스 플란타럼 hdb 균주 및 이를 포함하는 화장료 조성물 | |
| HK40121821A (zh) | 白癣治疗用组合物 | |
| Park et al. | Inhibitory effects of oral probiotics on biofilm formation, growth, and filament development in Candida albicans | |
| Ramezani et al. | Inhibitory effects of cell-free supernatant of Bifidobacterium bifidum on biofilm formation and virulence gene expression in Group B Streptococcus clinical isolates | |
| WO2024189071A1 (en) | Skin archaea preparation | |
| KR20240167319A (ko) | 아미노피롤니트린 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 소 피부사상균증 예방, 개선 또는 치료용 조성물 | |
| KR20260003714A (ko) | 피부 염증 치료에 유용한 신규 세균 균주 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241104 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241106 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241106 |